Friday, July 10, 2026

pharma · Advanced or metastatic solid tumors · Waldenström's Macroglobulinemia

BeiGene

BeiGene is a pharma organization headquartered in Camana Bay, KY. Primary therapeutic focus areas include Advanced or metastatic solid tumors, Waldenström's Macroglobulinemia, Covid19, Ovarian Cancer, Carcinoma, Hepatoce

55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US HQ
2010 Founded
2,047 Employees
NMPA registrant Type
Company details
Status
Public
HQ
55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US
Founded
2010
Employees
2,047
Programs
14
Drugs
19
Patents
25
Clinical program

BGB-21447-101

Phase 1 · other · mature B-Cell malignancies

BGB-21447-101 for mature B-Cell malignancies is a Phase 1 program (other) at BeiGene with 1 ClinicalTrials.gov record(s).

← All BeiGene projects Phase 1 other active

Internal code BGB-21447-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
BeiGene
Phase
Phase 1
Modality
other
Indication
mature B-Cell malignancies
Status
active
Trials
1